Aetna Health Inc. v. Davila

Gryt Health to Host Fifth Annual Global Virtual Cancer Conference (GVCC) in November

Retrieved on: 
Tuesday, October 24, 2023
Survivor, Hearing, Health, Human, Conference, Organization, Empowerment, Administration, Senior, Caregiver, Zoom, GVCC, Community, Education, Patient, Diagnosis, Cancer, Aetna Health Inc. v. Davila, Mental health, Residential care, Nursing

ROCHESTER, N.Y., Oct. 24, 2023 /PRNewswire-PRWeb/ -- Gryt ("grit") Health Inc, a patient experience and research company, is hosting the fifth annual Global Virtual Cancer Conference (GVCC) on November 3, 2023. GVCC is the original digital cancer conference created by a team of cancer survivors and caregivers. GVCC 2023 will address topics critical to improving cancer-related outcomes and experiences through a focus on advocacy. There will be a full day of interactive sessions encompassing timely topics for patients, survivors, and caregivers to empower them.

Key Points: 
  • Free Live Virtual Event Offers Cancer Connection, Education, and Advocacy For Everyone, On-Demand After
    ROCHESTER, N.Y., Oct. 24, 2023 /PRNewswire-PRWeb/ -- Gryt ("grit") Health Inc, a patient experience and research company, is hosting the fifth annual Global Virtual Cancer Conference (GVCC) on November 3, 2023.
  • GVCC is the original digital cancer conference created by a team of cancer survivors and caregivers.
  • There will be a full day of interactive sessions encompassing timely topics for patients, survivors, and caregivers to empower them.
  • "We are very excited for this year's Global Virtual Cancer Conference," said Lauren Lastauskas, Vice President of Community at Gryt Health.

Five Ovation-Supported Research Abstracts Presented at ASRM 2023

Retrieved on: 
Wednesday, October 18, 2023
Research, Vitrification, Fertility, Aetna Health Inc. v. Davila, Congress, Health, Poster, IVF, Valencian Community, San Francisco Bay Area, Reproductive medicine, CO, ICSI, Harbor, MD

Nashville, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Ovation® Fertility teams presented three poster and two oral presentations at the 2023 ASRM Scientific Congress & Expo, which takes place in New Orleans, Louisiana, October 14-18, 2023.

Key Points: 
  • Nashville, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Ovation® Fertility teams presented three poster and two oral presentations at the 2023 ASRM Scientific Congress & Expo, which takes place in New Orleans, Louisiana, October 14-18, 2023.
  • “ASRM is an event that we look forward to and work toward every year because it provides us so many opportunities to learn and share with other experts in reproductive medicine,” says Matthew “Tex” VerMilyea, Ph.D., HCLD/CC, Ovation’s vice president of scientific advancement.
  • “We are very excited to have been invited to showcase many of our latest research findings, produced in collaboration with our physician partners and key suppliers of advanced reproductive technologies, such as artificial intelligence.”
    This year’s Ovation-supported presentations covered advances in intracytoplasmic sperm injection (ICSI), embryo vitrification, and the use of AI in embryo selection.
  • O-1 – CLINICAL EVALUATION OF A MACHINE LEARNING MODEL FOR EMBRYO SELECTION: A DOUBLE-BLINDED RANDOMIZED COMPARATIVE READER STUDY
    (1)Reproductive Science Center of the San Francisco Bay Area, San Ramon, CA, (2)Alife Health, Inc., Cambridge, MA, (3)Alife Health, Inc., (4)Alife Health, Inc., San Francisco, CA, (5)CCRM Fertility, Lone Tree, CO, (6)IVF Florida Reproductive Associates, Margate, FL, (7)Ovation Fertility, Austin, TX
    (1)Ovation Fertility, San Antonio, TX, (2)Life Whisperer Diagnostics Inc (a subsidiary of Presagen), San Francisco, CA, (3)Australian Research Council Centre of Excellence for Nanoscale BioPhotonics, Adelaide, SA, Australia, (4)IVIRMA Global, Valencia, Spain, (5)IVI Foundation - La Fe Health Research Institute, Valencia, Comunidad Valenciana, Spain, (6)IVF Florida Reproductive Associates, Margate, FL, (7)Shady Grove Fertility, Rockville, MD, (8)Presagen and Life Whisperer, Adelaide, SA, Australia, (9)San Francisco Bay Area, Los Gatos, CA
    (1)Alife Health, Inc., San Francisco, CA, (2)Alife Health, Inc., (3)Boston IVF, Waltham, MA, (4)IVF Florida Reproductive Associates, Margate, FL, (5)Ovation Fertility, Austin, TX, (6) Reproductive Science Center of the San Francisco Bay Area, San Ramon, CA

3EO Health Receives NIH RADx® Tech Award to Expand Application of its 3TR Point of Care Technology

Retrieved on: 
Monday, October 16, 2023
Health, Medical Devices, Health Technology, Other Health, COVID-19, General Health, Biotechnology, Tech, National Institute of Biomedical Imaging and Bioengineering, Physician, Family, Biological engineering, Human services, United States Department of Health and Human Services, Medical imaging, Acceleration, Aetna Health Inc. v. Davila, Controversies regarding COVID-19 contracts in the United Kingdom, Chief Technology Officer of the United States, Federal, Bangladesh Technical Education Board, Overalls, National Institutes of Health, Work, Patient, NIH, Vaccine, Medical device

With the NIH RADx Tech award, 3EO Health will accelerate and expand the development and application of its novel 3TR technology into a multiplex format.

Key Points: 
  • With the NIH RADx Tech award, 3EO Health will accelerate and expand the development and application of its novel 3TR technology into a multiplex format.
  • "We are honored to be chosen as recipients of the RADx Tech award from NIBIB," said Jeremy Schubert, CEO of 3EO Health.
  • "3EO Health's innovative approach holds immense promise for the future of diagnostic testing," said Peter Honkanen M.S.M., B.S.E.E., Chief Technology officer of 3EO Health.
  • 3EO Health Inc. is a “Point of Life” diagnostic company leveraging novel technology to exponentially lower cost and expand clinical and community access to high impact diagnostic tools.

Eighty-seven (87) percent of Aetna Medicare Advantage members in 4-star plans or higher for 2024

Retrieved on: 
Friday, October 13, 2023
Investment, MAPD, NYSE, CVS Health, CVS, Breast cancer, CAHPS, HMO, PPO, Aetna, Aetna Health Inc. v. Davila, TTY, CMS, Medicare, Star, Medicare (United States), Centers for Medicare & Medicaid Services, MA, Health Star Rating System, Breast cancer screening, Pharmaceutical industry, Health insurance, Nursing

WOONSOCKET, R.I., Oct. 13, 2023 /PRNewswire/ -- Aetna®, a CVS Health® company (NYSE: CVS), announced today that 87 percent of its Medicare Advantage (MA) members are in 2024 Medicare Advantage Prescription Drug (MAPD) plans that are rated 4 stars or higher (out of 5 stars) by the Centers for Medicare & Medicaid Services (CMS). This represents a significant achievement, given the considerably more stringent CMS measurement criteria this year.

Key Points: 
  • WOONSOCKET, R.I., Oct. 13, 2023 /PRNewswire/ -- Aetna®, a CVS Health® company (NYSE: CVS), announced today that 87 percent of its Medicare Advantage (MA) members are in 2024 Medicare Advantage Prescription Drug (MAPD) plans that are rated 4 stars or higher (out of 5 stars) by the Centers for Medicare & Medicaid Services (CMS).
  • "We are committed to delivering outstanding experiences and driving improved health outcomes for our Medicare Advantage members," said CVS Health President and CEO Karen S. Lynch.
  • "Our strong 2024 Star Ratings for Aetna are a result of focused execution and seamless collaboration across our entire company.
  • Visit AetnaMedicare.com to learn more about the 2024 Aetna Medicare plans.

Verséa Health, Inc. Launches Verséa Easy Lab™, Affordable, Highly Accurate Over-the-Counter (OTC) Product Line

Retrieved on: 
Tuesday, August 15, 2023
Health, FDA, Medical Devices, General Health, Research, Science, Pharmaceutical, Ovulation, Pregnancy, Therapy, Stool test, Aetna Health Inc. v. Davila

Verséa Health, Inc. (“ Verséa ”), a Florida-based health care company engaged in the commercialization of innovative diagnostics and therapeutics, has launched the Verséa Easy Lab™ product line of rapid, at-home, over-the-counter diagnostic tests that will be sold at retail locations nationwide.

Key Points: 
  • Verséa Health, Inc. (“ Verséa ”), a Florida-based health care company engaged in the commercialization of innovative diagnostics and therapeutics, has launched the Verséa Easy Lab™ product line of rapid, at-home, over-the-counter diagnostic tests that will be sold at retail locations nationwide.
  • The affordable, FDA approved, and professional quality tests will enable people to check up on their health at any time and in the comfort of their homes.
  • James Olin, Chief Commercial Officer at Verséa Health, Inc. explained the reason behind the launch: “The Verséa Easy Lab™ product line was created with a mission to give millions of Americans direct access to the most essential and necessary health care services with an emphasis on prediction, prevention, and value.
  • This launch also strategically fits with our focus on supporting new and more accessible locations of care like urgent care clinics and independent community pharmacies.”
    To learn more about Verséa Health, Inc. and the Verséa Easy Lab™ product line, visit the Verséa Health webpage or contact directly at [email protected] or 1-800-397-0670

Syntax Launches Two-sided Enterprise SaaS-based Solution to Accelerate Alignment and Adoption in Value-based Care for Healthcare Plans and Providers

Retrieved on: 
Thursday, June 8, 2023
Data Management, Health, Technology, Health Technology, Software, General Health, Healthcare Financial Management Association, Software as a service, CMS, Senior, Centers for Medicare & Medicaid Services, Health care, VBC, Center for Medicare and Medicaid Innovation, Aetna Health Inc. v. Davila, Medicare, Friction, Trust, Partnership, Syntax, HFMA, Health insurance, Risk management, Signify

The team-centric enterprise solution drives transparency, collaboration and consistency, and facilitates best-fit payment model design in real-time.

Key Points: 
  • The team-centric enterprise solution drives transparency, collaboration and consistency, and facilitates best-fit payment model design in real-time.
  • However, insufficient technology to implement value-based care models, a hesitancy to accept financial risk, opposing incentives and no established contract blueprint remain key barriers to adoption.
  • “We created Syntax to fill these gaps, providing every team member the analytics, infrastructure and a collaborative two-sided workspace needed to accelerate adoption.
  • Syntax was built at Redesign Health by Rachael Jones and the founding team, and has raised $7.5 million in seed funding.

Large-Scale, Parallel-Track Survey Focused on Women's Health Shows Discrepancies Between Patient Preferences and Healthcare Professional Perceptions of Factors Influencing Contraceptive Use in the United States

Retrieved on: 
Thursday, May 18, 2023
Pregnancy, FPS, HealthyWomen, USB On-The-Go, Birth, Woman, Intrauterine device, Aetna Health Inc. v. Davila, HCP, Research and development, Development, Roe v. Wade, MD, Patient, Supreme court, Menstrual cycle, Advance for NPs & PAs, Knowledge, Condom, Ageing, Health, Zauderer v. Office of Disciplinary Counsel of Supreme Court of Ohio, Birth control, MPH

ROSWELL, Ga., May 18, 2023 /PRNewswire/ -- Sebela Women's Health Inc., a part of Sebela Pharmaceuticals, today announced results of a large-scale, parallel-track national survey of women and healthcare professionals (HCPs) conducted by HealthyWomen, the nation's leading independent nonprofit health resource for women. The survey was designed to assess current knowledge and understanding of birth control usage, affordability and beliefs in the United States at a time when women's healthcare choices are being limited or revoked. The survey identified discrepancies in healthcare professional perceptions of their patients' preferences about birth control and factors that influence selection. The survey also sought to explore possible reasons why, despite increased availability of birth control options for women over the past two decades, 45% of pregnancies in the U.S. remain unplanned.1

Key Points: 
  • The survey was designed to assess current knowledge and understanding of birth control usage, affordability and beliefs in the United States at a time when women's healthcare choices are being limited or revoked.
  • The survey identified discrepancies in healthcare professional perceptions of their patients' preferences about birth control and factors that influence selection.
  • The parallel-track survey consisted of more than 5,000 women aged 18-55 (n=5,052) and 506 HCPs (OB/GYNs, NPs/PAs and FPs).
  • Survey respondents were recruited through a proprietary market panel and the patient survey was balanced to U.S. census for race and ethnicity.

AIS Healthcare Announces New Hire to Legal Team

Retrieved on: 
Wednesday, April 26, 2023
Professional Services, Nursing, Health, Legal, Managed Care, Pharmaceutical, Aetna Health Inc. v. Davila, Law, Chronic pain, Young, Patient, Spasticity, AIS, Pharmacy, Princeton University, Medical device

AIS Healthcare, the leading provider of targeted drug delivery and infusion care solutions, today announced the hiring of Thomas Young as Deputy General Counsel and Deputy Chief Compliance Officer.

Key Points: 
  • AIS Healthcare, the leading provider of targeted drug delivery and infusion care solutions, today announced the hiring of Thomas Young as Deputy General Counsel and Deputy Chief Compliance Officer.
  • In this role, Thomas will drive AIS Healthcare’s legal strategy, help oversee the company’s regulatory and compliance programs, and lead engagement with state and federal regulators.
  • “We are thrilled to welcome an experienced and highly respected member of the healthcare industry to the AIS Healthcare team,” said John Finley, AIS Healthcare’s General Counsel and Chief Compliance Officer.
  • “I’m excited to join AIS Healthcare’s industry leading team and offer my experience to further enhance the company’s efforts to advance quality and compliance standards for specialty pharmacies,” said Thomas Young, AIS Healthcare’s Deputy General Counsel and Deputy Chief Compliance Officer.

AM Best Affirms Credit Ratings of CVS Health Corporation’s Aetna Inc. Subsidiaries

Retrieved on: 
Wednesday, March 29, 2023
Insurance, Professional Services, Aetna, ERM, Public, Coventry Health Care, Medicare, Baptist Health South Florida, Allina Health, MinuteClinic, Relaxation, News, NYSE, AM Best, Life, CVS, Federal Home Loan Banks, Growth, Credit, ROE, Aetna Health Inc. v. Davila, University of North Texas Health Science Center, Cell, ALL, Parent, COVID-19, Health, CVS Health, Bermuda, BA, Goodwill, Redetermination, ROR, FSR, AM, Oak Street Health, Long-term care insurance, Health insurance, Financial services, Nursing, Medicaid

AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “a” (Excellent) of Aetna Life Insurance Company (ALIC) (Hartford, CT) and the other members of Aetna Health & Life Group, which are operating entities of Aetna Inc. (Aetna) and wholly owned subsidiaries of CVS Health Corporation (CVS Health) [NYSE: CVS].

Key Points: 
  • AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “a” (Excellent) of Aetna Life Insurance Company (ALIC) (Hartford, CT) and the other members of Aetna Health & Life Group, which are operating entities of Aetna Inc. (Aetna) and wholly owned subsidiaries of CVS Health Corporation (CVS Health) [NYSE: CVS].
  • Concurrently, AM Best has affirmed the FSR of A (Excellent) and the Long-Term ICRs of “a” (Excellent) of Texas Health + Aetna Health Insurance Company, as well as Texas Health + Aetna Health Plan Inc.
  • Texas Health Aetna and Allina Health and Aetna Insurance Company are joint ventures with subsidiaries of Aetna Inc.
  • The ratings of Aetna Health & Life Group reflect the ultimate parent, CVS Health, and an expectation of elevated leverage due to the recently announced acquisitions.

Sebela Women's Health Shares Findings from a Real-World Cost Comparison of Hormonal and Non-hormonal IUD Use Among Privately Insured Individuals in the U.S.

Retrieved on: 
Tuesday, March 21, 2023
Database, University, Obstetrics, IUD, Associate professor, Obstetrics and gynaecology, Birth, Woman, Levonorgestrel, Intrauterine device, Bayer, Incidence, Patient, The Cooper Companies, Gynaecology, Ageing, Copper, FDA, Aetna Health Inc. v. Davila, Medicine, Birth control, Pharmaceutical industry, LNG

ROSWELL, Ga., March 21, 2023 /PRNewswire/ -- Sebela Women's Health Inc, a part of Sebela Pharmaceuticals, will present findings from a post-hoc comparison of payer costs for hormonal and non-hormonal intrauterine devices (IUDs) during the Academy of Managed Care Pharmacy Congress, March 21-24, 2023, in San Antonio, TX. Seven years of U.S. commercial claims data were analyzed to improve estimates of long-term, real-world costs, with specific attention to costs related to IUD complications and device removals.

Key Points: 
  • The study included paid claims from individuals aged 12-45 years who had an IUD inserted in 2014 and were continuously enrolled for one year prior and after the insertion of a new IUD.
  • The cohort included 45,709 (72.1%) individuals with a hormonal IUD (13.5mg [Skyla®] or 52mg levonorgestrel (LNG)-releasing [Mirena®]) and 8,035 (12.7%) with a non-hormonal (copper-based [Paragard®]) IUD.
  • The data—obtained from MarketScan®, a commercial claims database from Merative™—were examined using diagnosis codes for procedures and services related to IUD use.
  • Costs due to complications incorporated any paid claims associated with known adverse events during the time of IUD use.